@article { , title = {Arginine methylation: the promise of a ‘silver bullet’ for brain tumours?}, abstract = {Despite intense research efforts, our pharmaceutical repertoire against high-grade brain tumours has not been able to increase patient survival for a decade and life expectancy remains at less than 16months after diagnosis, on average. Inhibitors of protein arginine methyltransferases (PRMTs) have been developed and investigated over the past 15years and have now entered oncology clinical trials, including for brain tumours. This review collates recent advances in the understanding of the role of PRMTs and arginine methylation in brain tumours. We provide an up-to-date literature review on the mechanisms for PRMT regulation. These include endogenous modulators such as alternative splicing, miRNA, post-translational modifications and PRMT–protein interactions, and synthetic inhibitors. We discuss the relevance of PRMTs in brain tumours with a particular focus on PRMT1, -2, -5 and -8. Finally, we include a future perspective where we discuss possible routes for further research on arginine methylation and on the use of PRMT inhibitors in the context of brain tumours.}, doi = {10.1007/s00726-020-02937-x}, eissn = {1438-2199}, issn = {0939-4451}, issue = {4}, journal = {Amino Acids}, pages = {489-506}, publicationstatus = {Published}, publisher = {Springer Verlag}, url = {https://hull-repository.worktribe.com/output/3679426}, volume = {53}, keyword = {Health and Health Inequalities, Arginine methylation, Brain tumours, Glioblastoma, Inhibitors, Post-translational modifications, Protein arginine methyltransferases}, year = {2021}, author = {Samuel, Sabrina F and Barry, Antonia and Greenman, John and Beltran-Alvarez, Pedro} }